{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T20:19:08Z","timestamp":1760473148163,"version":"build-2065373602"},"reference-count":56,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","doi-asserted-by":"publisher","award":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2019","CEECIND\/00630\/2017"],"award-info":[{"award-number":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2019","CEECIND\/00630\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"CEECIND 2017","doi-asserted-by":"publisher","award":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2019","CEECIND\/00630\/2017"],"award-info":[{"award-number":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2019","CEECIND\/00630\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Ruthenium complexes are emerging as one of the most promising classes of complexes for cancer therapy. However, their limited aqueous solubility may be the major limitation to their potential clinical application. In view and to contribute to the progress of this field, eight new water-soluble Ru(II) organometallic complexes of general formula [RuCp(mTPPMS)n(L)] [CF3SO3], where mTPPMS = diphenylphosphane-benzene-3-sulfonate, for n = 2, L is an imidazole-based ligand (imidazole, 1-benzylimidazole, 1-butylimidazole, (1-(3-aminopropyl)imidazole), and (1-(4-methoxyphenyl)imidazole)), and for n = 1, L is a bidentate heteroaromatic ligand (2-benzoylpyridine, (di(2-pyridyl)ketone), and (1,2-(2-pyridyl)benzo-[b]thiophene)) were synthesized and characterized. The new complexes were fully characterized by NMR, FT-IR, UV\u2013vis., ESI-HRMS, and cyclic voltammetry, which confirmed all the proposed molecular structures. The antiproliferative potential of the new Ru(II) complexes was evaluated on MDAMB231 breast adenocarcinoma, A2780 ovarian carcinoma, and HT29 colorectal adenocarcinoma cell lines, showing micromolar (MDAMB231 and HT29) and submicromolar (A2780) IC50 values. The interaction of complex 6 with human serum albumin (HSA) and fatty-acid-free human serum albumin (HSAfaf) was evaluated by fluorescence spectroscopy techniques, and the results revealed that the ruthenium complex strongly quenches the intrinsic fluorescence of albumin in both cases.<\/jats:p>","DOI":"10.3390\/ph15070862","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T01:57:11Z","timestamp":1657850231000},"page":"862","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Design and Anticancer Properties of New Water-Soluble Ruthenium\u2013Cyclopentadienyl Complexes"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8243","authenticated-orcid":false,"given":"T\u00e2nia S.","family":"Morais","sequence":"first","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-5299","authenticated-orcid":false,"given":"Fernanda","family":"Marques","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10 (km 139,7), 2695-066 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9922-7392","authenticated-orcid":false,"given":"Paulo J. Amorim","family":"Madeira","sequence":"additional","affiliation":[{"name":"Ascenza Agro, SA, Av. do Rio Tejo-Parq. Ind. Sapec Bay, 2910-440 Set\u00fabal, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-6910","authenticated-orcid":false,"given":"Maria Paula","family":"Robalo","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal"}]},{"given":"Maria Helena","family":"Garcia","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1039\/C2CS35314H","article-title":"Metal N-Heterocyclic Carbene Complexes as Potential Antitumor Metallodrugs","volume":"42","author":"Liu","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic Anticancer Compounds","volume":"54","author":"Gasser","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12114","DOI":"10.1002\/ange.201602814","article-title":"Cyclometalated Palladium(II) N-Heterocyclic Carbene Complexes: Anticancer Agents for Potent In Vitro Cytotoxicity and In Vivo Tumor Growth Suppression","volume":"128","author":"Fong","year":"2016","journal-title":"Angew. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1039\/C7CS00195A","article-title":"The Development of Anticancer Ruthenium(II) Complexes: From Single Molecule Compounds to Nanomaterials","volume":"46","author":"Zeng","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/anie.201311161","article-title":"The Potent Oxidant Anticancer Activity of Organoiridium Catalysts","volume":"53","author":"Liu","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/cr400135x","article-title":"Advances in Copper Complexes as Anticancer Agents","volume":"114","author":"Santini","year":"2013","journal-title":"Chem. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1039\/b601840h","article-title":"Metal-Based Antitumour Drugs in the Post Genomic Era","volume":"16","author":"Dyson","year":"2006","journal-title":"Dalton Trans."},{"key":"ref_9","first-page":"183","article-title":"Antitumour Metal Compounds: More than Theme and Variations","volume":"2","author":"Jakupec","year":"2007","journal-title":"Dalton Trans."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1039\/C9CC04098F","article-title":"Functionalization and Cancer-Targeting Design of Ruthenium Complexes for Precise Cancer Therapy","volume":"55","author":"Liu","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1021\/acs.jmedchem.7b01689","article-title":"Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?","volume":"61","author":"Thota","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16113","DOI":"10.1039\/C7DT03369A","article-title":"Aminophosphine Ligands as a Privileged Platform for Development of Antitumoral Ruthenium(II) Arene Complexes","volume":"46","author":"Broomfield","year":"2017","journal-title":"Dalton Trans."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1039\/C7CS00332C","article-title":"Structure\u2013Activity Relationships for Ruthenium and Osmium Anticancer Agents\u2014Towards Clinical Development","volume":"47","author":"Gerner","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114827","DOI":"10.1016\/j.poly.2020.114827","article-title":"Recent Advances in Cytotoxicity, Cellular Uptake and Mechanism of Action of Ruthenium Metallodrugs: A Review","volume":"192","author":"Sudhindra","year":"2020","journal-title":"Polyhedron"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-010-1293-1","article-title":"Ruthenium-Based Chemotherapeutics: Are They Ready for Prime Time?","volume":"66","author":"Antonarakis","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-03-0746","article-title":"A Phase I and Pharmacological Study with Imidazolium-Trans-DMSO-Imidazole-Tetrachlororuthenate, a Novel Ruthenium Anticancer Agent","volume":"10","author":"Pluim","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II Study with Ruthenium Compound NAMI-A and Gemcitabine in Patients with Non-Small Cell Lung Cancer after First Line Therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbdv.200890195","article-title":"KP1019, A New Redox-Active Anticancer Agent\u2014Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients","volume":"5","author":"Hartinger","year":"2008","journal-title":"Chem. Biodivers."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jinorgbio.2006.02.013","article-title":"From Bench to Bedside\u2014Preclinical and Early Clinical Development of the Anticancer Agent Indazolium Trans-[Tetrachlorobis(1H-Indazole)Ruthenate(III)] (KP1019 or FFC14A)","volume":"100","author":"Hartinger","year":"2006","journal-title":"J. Inorg. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1039\/C3SC53243G","article-title":"NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application","volume":"5","author":"Trondl","year":"2014","journal-title":"Chem. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Alessio, E., and Messori, L. (2019). NAMI-A and KP1019\/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules, 24.","DOI":"10.3390\/molecules24101995"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1039\/C4DT01645A","article-title":"Improved Reaction Conditions for the Synthesis of New NKP-1339 Derivatives and Preliminary Investigations on Their Anticancer Potential","volume":"44","author":"Kuhn","year":"2014","journal-title":"Dalton Trans."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1039\/c4pp00438h","article-title":"A Novel Class of Ruthenium-Based Photosensitizers Effectively Kills in Vitro Cancer Cells and in Vivo Tumors","volume":"14","author":"Fong","year":"2015","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chen, Q., Ramu, V., Aydar, Y., Groenewoud, A., Zhou, X.Q., Jager, M.J., Cole, H., Cameron, C.G., McFarland, S.A., and Bonnet, S. (2020). TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models. Cancers, 12.","DOI":"10.3390\/cancers12030587"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119858","DOI":"10.1016\/j.ica.2020.119858","article-title":"Ruthenium and Iridium Based Mononuclear and Multinuclear Complexes: A Breakthrough of Next-Generation Anticancer Metallopharmaceuticals","volume":"512","author":"Kar","year":"2020","journal-title":"Inorg. Chim. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1039\/c3md00367a","article-title":"Arene Ruthenium(II) Complexes Induce S-Phase Arrest in MG-63 Cells through Stabilization of c-Myc G-Quadruplex DNA","volume":"5","author":"Fan","year":"2014","journal-title":"MedChemComm"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1021\/jm070039f","article-title":"Development of Ruthenium Antitumor Drugs That Overcome Multidrug Resistance Mechanisms","volume":"50","author":"Vock","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1039\/C8NJ04159H","article-title":"Enhancement of Therapeutic Effect in Breast Cancer with a Steroid-Conjugated Ruthenium Complex","volume":"43","author":"Lv","year":"2019","journal-title":"New J. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9164","DOI":"10.1021\/ic201388n","article-title":"A Potent Ruthenium(II) Antitumor Complex Bearing a Lipophilic Levonorgestrel Group","volume":"50","author":"Ruiz","year":"2011","journal-title":"Inorg. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1039\/D0QI01344G","article-title":"Unprecedented Collateral Sensitivity for Cisplatin-Resistant Lung Cancer Cells Presented by New Ruthenium Organometallic Compounds","volume":"8","author":"Teixeira","year":"2021","journal-title":"Inorg. Chem. Front."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1039\/C7DT03385K","article-title":"Tuning the Cytotoxicity of Ruthenium(II) Para-Cymene Complexes by Mono-Substitution at a Triphenylphosphine\/Phenoxydiphenylphosphine Ligand","volume":"46","author":"Biancalana","year":"2017","journal-title":"Dalton Trans."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1039\/C4SC01255K","article-title":"In Vivo Anti-Tumor Activity of the Organometallic Ruthenium(II)-Arene Complex [Ru(H6-p-Cymene)Cl2(Pta)] (RAPTA-C) in Human Ovarian and Colorectal Carcinomas","volume":"5","author":"Weiss","year":"2014","journal-title":"Chem. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2533\/chimia.2007.698","article-title":"Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-Clinical Development","volume":"61","author":"Dyson","year":"2007","journal-title":"CHIMIA Int. J. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00775-014-1120-y","article-title":"Anticancer Activity of Structurally Related Ruthenium(II) Cyclopentadienyl Complexes","volume":"19","author":"Mendes","year":"2014","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1017\/S143192761300175X","article-title":"Cellular Uptake Mechanisms of an Antitumor Ruthenium Compound: The Endosomal\/Lysosomal System as a Target for Anticancer Metal-Based Drugs","volume":"19","author":"Matos","year":"2013","journal-title":"Microsc. Microanal."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc.16.7","article-title":"Tracking Antitumor Metallodrugs: Promising Agents with the Ru(II)- and Fe(II)-Cyclopentadienyl Scaffolds","volume":"8","author":"Morais","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jinorgbio.2012.04.014","article-title":"Synthesis of Organometallic Ruthenium(II) Complexes with Strong Activity against Several Human Cancer Cell Lines","volume":"114","author":"Morais","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/1871520619666190318152726","article-title":"Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools","volume":"19","author":"Gano","year":"2019","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_39","first-page":"126","article-title":"In Vivo Performance of a Ruthenium-Cyclopentadienyl Compound in an Orthotopic 1 Triple Negative Breast Cancer Model","volume":"16","author":"Mendes","year":"2016","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.09.013","article-title":"New Water-Soluble Ruthenium(II) Cytotoxic Complex: Biological Activity and Cellular Distribution","volume":"130","author":"Morais","year":"2014","journal-title":"J. Inorg. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1016\/j.jorganchem.2006.04.037","article-title":"Half-Sandwich H6-Benzene Ru(II) Complexes of Pyridylpyrazole and Pyridylimidazole Ligands: Synthesis, Spectra, and Structure","volume":"691","author":"Mishra","year":"2006","journal-title":"J. Organomet. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1570-0232(02)00004-1","article-title":"Relationship between Lipophilicity and Antitumor Activity of Molecule Library of Mannich Ketones Determined by High-Performance Liquid Chromatography, ClogP Calculation and Cytotoxicity Test","volume":"768","author":"Idei","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jinorgbio.2011.01.013","article-title":"Copper(II) Complexes with Tridentate Pyrazole-Based Ligands: Synthesis, Characterization, DNA Cleavage Activity and Cytotoxicity","volume":"105","author":"Gama","year":"2011","journal-title":"J. Inorg. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1039\/b927129p","article-title":"Issues Surrounding Standard Cytotoxicity Testing for Assessing Activity of Non-Covalent DNA-Binding Metallo-Drugs","volume":"39","author":"Pope","year":"2010","journal-title":"Dalton Trans."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1039\/b926233d","article-title":"Tuning the Electronic Properties of Dppz-Ligands and Their Palladium(II) Complexes","volume":"39","author":"Butsch","year":"2010","journal-title":"Dalton Trans."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lakowicz, J.R. (2006). Principles of Fluorescence Spectroscopy, Springer.","DOI":"10.1007\/978-0-387-46312-4"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijbiomac.2010.08.002","article-title":"Investigation on the Interaction between Tamoxifen and Human Holo-Transferrin: Determination of the Binding Mechanism by Fluorescence Quenching, Resonance Light Scattering and Circular Dichroism Methods","volume":"47","author":"Sarzehi","year":"2010","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Valeur, B., and Berberan-Santos, M.N. (2013). Molecular Fluorescence: Principles and Applications, Wiley-VCH.","DOI":"10.1002\/9783527650002"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jinorgbio.2013.09.008","article-title":"Exploring the Effect of the Ligand Design on the Interactions between [Ru(H5-C5H5)(PPh3)(N,O)][CF3SO3] Complexes and Human Serum Albumin","volume":"129","author":"Morais","year":"2013","journal-title":"J. Inorg. Biochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jphotobiol.2014.08.020","article-title":"Binding of Hydroxylated Single-Walled Carbon Nanotubes to Two Hemoproteins, Hemoglobin and Myoglobin","volume":"141","author":"Wang","year":"2014","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1002\/ejic.200601177","article-title":"DNA Interactions Mediated by Cyclopentadienidoruthenium(II) Complexes Containing Water-Soluble Phosphanes","volume":"2007","author":"Romerosa","year":"2007","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chroma.2004.01.001","article-title":"Determination of Liquid-Liquid Partition Coefficients by Separation Methods","volume":"1037","author":"Berthod","year":"2004","journal-title":"J. Chromatogr. A"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.toxlet.2005.07.001","article-title":"In Vitro Cytotoxicity Assays: Comparison of LDH, Neutral Red, MTT and Protein Assay in Hepatoma Cell Lines Following Exposure to Cadmium Chloride","volume":"160","author":"Fotakis","year":"2006","journal-title":"Toxicol. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1432-1033.1974.tb03295.x","article-title":"A Spectroscopic Study of the Haemin\u2013Human-Serum-Albumin System","volume":"41","author":"Beaven","year":"1974","journal-title":"Eur. J. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1039\/AN9941900417","article-title":"Experimental Correction for the Inner-Filter Effect in Fluorescence Spectra","volume":"119","author":"Kubista","year":"1994","journal-title":"Analyst"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1021\/ed070p425","article-title":"Ribonuclease T1 and Alcohol Dehydrogenase Fluorescence Quenching by Acrylamide: A Laboratory Experiment for Undergraduate Students","volume":"70","author":"Coutinho","year":"1993","journal-title":"J. Chem. Educ."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/7\/862\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:50:21Z","timestamp":1760140221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/7\/862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ph15070862"],"URL":"https:\/\/doi.org\/10.3390\/ph15070862","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}